Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BETAXOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BETAXOLOL HYDROCHLORIDE.
BETAPACE vs BETAXOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
10-20 mg orally once daily; maximum 20 mg/day.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Category C
Category C
Beta-Blocker
Beta-Blocker